- Home
- GLPG
GLPG
Galapagos NV
as 01-22-2025 4:00pm EST
| Founded: | 1999 | Country: | Belgium |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | 2005 |
| Target Price: | $30.75 | AVG Volume (30 days): | 237.1K |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.49 - $40.34 | Next Earning Date: | 02-12-2025 |
| Revenue: | $290,089,226 | Revenue Growth: | -52.19% |
| Revenue Growth (this year): | 33.27% | Revenue Growth (next year): | -13.37% |
Latest Galapagos NV News
GLPG Breaking Stock News: Dive into GLPG Ticker-Specific Updates for Smart Investing
MT Newswires
15 days ago
Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%
GlobeNewswire
15 days ago
Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities
GlobeNewswire
15 days ago
Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Simply Wall St.
a month ago
Galapagos NV (AMS:GLPG) stock most popular amongst retail investors who own 56%, while public companies hold 25%
Clinical Trials Arena
a month ago
ASH 2024: Galapagos presents positive results for a seven-day ‘vein-to-vein’ CAR T-cell therapy
GlobeNewswire
2 months ago
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
GlobeNewswire
3 months ago
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
Simply Wall St.
3 months ago
Galapagos Third Quarter 2024 Earnings: €0.74 loss per share (vs €0.39 profit in 3Q 2023)
Compare GLPG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GLPG Galapagos NV - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.